EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Reversal of MPPa ‐ PDT Resistance in Osteosarcoma by Targeting ROCK2 ‐Mediated Autophagy

Xuan Yi iD, Xueqiang Deng iD, Jianyong Deng, Chen Li, Hong Peng, Yunyan Du, Qing Li, Xiaohua Yan iD, Xin Hu, Yan Zheng, Shenliang Chen, Ting Xiong and 3 more

Cell Proliferation · 2025

DOI: 10.1111/cpr.70097 ↗

At a glance

Journal article in Cell Proliferation, 2025. Written by Xuan Yi and 14 co-authors. Institution: Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Major MEDLINE topics: rho-Associated Kinases, Osteosarcoma, Autophagy, Drug Resistance, Neoplasm. 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Jiangxi Provincial Department of Science and Technology, Education Department of Jiangxi Province.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Osteosarcoma (OS) is a primary bone tumour that occurs mostly in adolescents and is associated with a high degree of malignancy, early metastasis, and poor prognosis. Pyropheophorbide‐a methyl ester‐Photodynamic therapy (MPPa‐PDT) is a new approach for the clinical treatment of osteosarcoma that develops after surgery and radiotherapy; however, the presence of MPPa‐PDT resistance in osteosarcoma greatly limits its efficacy. In this study, we found that Rho‐associated coiled‐coil containing protein kinase 2 (ROCK2) expression increased in osteosarcoma cells after MPPa‐PDT treatment. ROCK2 inhibition results in osteosarcoma sensitivity to MPPa‐PDT and is accompanied by a decrease in cellular autophagy levels. Rescue experiments further showed that ROCK2 mediates MPPa‐PDT resistance in osteosarcoma by regulating autophagy. Mechanistic studies have shown that ROCK2 mediates autophagy in osteosarcoma cells by regulating the Hippo signalling pathway. ROCK2 overexpression resulted in increased levels of the ROCK2‐Salvador homology 1 (SAV1) complex and decreased levels of the mammalian STE20‐like protein kinase 1 (MST1)‐SAV1 complex, thereby inhibiting activation of the Hippo pathway, which in turn led to osteosarcoma MPPa‐PDT resistance by regulating cellular autophagy. ROCK2 competes with MST1 for binding to the aa 28–198 region of SAV1. We also confirmed from a clinical perspective that ROCK2 is an independent prognostic factor in patients with osteosarcoma, is associated with worse patient prognosis, and correlates with the Hippo pathway. Targeted inhibition of ROCK2 by screening for J059‐0149 increases the sensitivity of osteosarcoma to MPPa‐PDT. In conclusion, our study establishes a novel mechanism to reverse MPPa‐PDT resistance in osteosarcoma by targeting ROCK2‐mediated autophagy, providing new targets and research ideas for the clinical treatment of osteosarcoma MPPa‐PDT resistance.

Subjects

MeSH terms (MEDLINE)

rho-Associated KinasesOsteosarcomaAutophagyDrug Resistance, NeoplasmBone NeoplasmsPhotochemotherapyHumansCell Line, TumorAnimalsSignal Transduction

Author keywords

MPPa‐PDTROCK2autophagyhippo pathwayosteosarcoma

Substances

rho-Associated KinasesROCK2 protein, human

Authors and institutions

  • Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Institute of Orthopedics of Jiangxi Province, Nanchang, China.
  • Jiangxi Provincial Key Laboratory of Spine and Spinal Cord Disease, Nanchang, China.
  • Institute of Minimally Invasive Orthopedics, Nanchang University, Nanchang, China.
  • Department of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Vascular & Interventional & Lymphatic Surgery, The First Hospital of Nanchang, Nanchang, China.

ORCID profiles: Xuan Yi, Xueqiang Deng, Xiaohua Yan

Funding

  • National Natural Science Foundation of China
  • Jiangxi Provincial Department of Science and Technology
  • Education Department of Jiangxi Province
  • The Ganpo Talent Program-Innovative Leadership Talent Project
  • The Medical Engineering Cross Innovation Foundation of Nanchang University

Cite

APA

Yi, X., Deng, X., Deng, J., Li, C., Peng, H., Du, Y., Li, Q., Yan, X., Hu, X., Zheng, Y., Chen, S., Xiong, T., Xu, D., Chen, L., & Hao, L. (2025). Reversal of MPPa ‐ PDT Resistance in Osteosarcoma by Targeting ROCK2 ‐Mediated Autophagy. Cell Proliferation. https://doi.org/10.1111/cpr.70097

Vancouver

Yi X, Deng X, Deng J, Li C, Peng H, Du Y, et al. Reversal of MPPa ‐ PDT Resistance in Osteosarcoma by Targeting ROCK2 ‐Mediated Autophagy. Cell Proliferation. 2025. doi:10.1111/cpr.70097

BibTeX
@article{Yi2025,
  author = {Yi, Xuan and Deng, Xueqiang and Deng, Jianyong and Li, Chen and Peng, Hong and Du, Yunyan and Li, Qing and Yan, Xiaohua and Hu, Xin and Zheng, Yan and Chen, Shenliang and Xiong, Ting and Xu, Debin and Chen, Leifeng and Hao, Liang},
  title = {Reversal of MPPa ‐ PDT Resistance in Osteosarcoma by Targeting ROCK2 ‐Mediated Autophagy},
  journal = {Cell Proliferation},
  year = {2025},
  doi = {10.1111/cpr.70097}
}
Start for free →